ANKYLOSING SPONDYLITIS — HLA-B27

Ankylosing Spondylitis — HLA-B27 present in 90-95% of patients but still taking an average of 7-10 years to diagnose, during which irreversible sacroiliac and spinal joint damage accumulates without anti-inflammatory treatment.

Whole genome sequencing provides complete HLA-B allele typing — identifying the specific HLA-B27 subtype with differential disease risk — supporting earlier diagnosis of inflammatory back pain and enabling prompt access to biologic therapy that prevents structural damage.

HLA-B

About this condition

Ankylosing Spondylitis — HLA-B27

Ankylosing spondylitis (AS), also called radiographic axial spondyloarthritis (r-axSpA), is a chronic immune-mediated inflammatory arthritis predominantly affecting the sacroiliac joints and spine. AS affects approximately 0.1-0.5% of European populations and is strongly associated with HLA-B27 — present in 90-95% of AS patients in European populations, compared to approximately 8% of the general European population. Despite this strong genetic signal, the average time from symptom onset to AS diagnosis is 7-10 years, during which active spinal inflammation causes progressive structural damage — sacroiliac erosion, syndesmophyte formation, and eventual vertebral fusion ('bamboo spine') — that is preventable with early biologic therapy.

HLA-B27 is not a single allele but a family of closely related variants. Over 170 HLA-B27 subtypes have been described (B*27:02 through B*27:173). The common disease-associated subtypes in European populations (B*27:05, B*27:02) carry the highest AS risk. B*27:06 (common in Southeast Asia) and B*27:09 (in Sardinia) are associated with dramatically lower AS risk despite sharing most of the B27 protein structure — a finding that has informed understanding of the pathogenic mechanism. B*27:01 is rare and also associated with low disease risk. Complete HLA-B27 subtype determination, rather than a simple B27 positive/negative result, provides clinically meaningful information about the level of AS risk in a B27-positive individual, particularly relevant for non-European ancestry populations.

The clinical utility of HLA-B27 typing in AS lies primarily in accelerating diagnosis. In a young adult presenting with inflammatory back pain (onset <45 years, insidious onset, morning stiffness >30 minutes, improvement with exercise, no improvement with rest), HLA-B27 positivity combined with suggestive imaging makes an AS diagnosis highly likely — ASAS classification criteria for axial spondyloarthritis include HLA-B27 as a major criterion. The biological rationale for damage prevention with early TNF inhibitor or IL-17 inhibitor treatment is well-established: these therapies suppress spinal inflammation but do not reverse established structural lesions. HLA-B27 testing in the early phase of inflammatory back pain is cost-effective if it accelerates time to diagnosis and biologic therapy by even 1-2 years.

HLA-B*27:06 (Southeast Asian populations) and B*27:09 (Sardinia) carry dramatically lower AS risk despite a B27-positive test result. Subtype identification from whole genome sequencing distinguishes truly high-risk B27 from low-risk subtypes.

Gene locus: HLA-B (6p21.33)

Standard HLA-B27 commercial tests report positive/negative without subtype. Complete HLA-B typing from whole genome sequencing identifies the specific B27 subtype — differentiating high-risk from low-risk subtypes that are clinically indistinguishable by standard testing.

HLA-B27:06 tests B27-positive but confers much lower AS risk than B27:05 — subtype matters

Standard HLA-B27 commercial assays report a dichotomous B27-positive or B27-negative result. B*27:06, common in Thai and other Southeast Asian populations, tests positive on standard HLA-B27 assays — but carries dramatically lower AS risk. A Southeast Asian patient who tests B27-positive and is counseled that they have 'a high-risk allele for ankylosing spondylitis' may receive inaccurate risk information if they carry B*27:06 rather than B*27:05 or B*27:02. Complete HLA-B allele typing at 4-digit field resolution from whole genome sequencing identifies the precise B27 subtype, enabling accurate risk stratification and appropriate counseling.

The same test that evaluates HLA-B27 also covers all other pharmacogenomically actionable HLA alleles

AS patients receiving biologic therapy — TNF inhibitors (adalimumab, etanercept) or IL-17 inhibitors (secukinumab, ixekizumab) — are often also managed for comorbidities requiring medications with HLA pharmacogenomic considerations. The same HLA-B*27 status from whole genome sequencing is generated alongside HLA-B*57:01 (abacavir risk), HLA-B*15:02 (carbamazepine risk in Asian patients), and HLA-B*58:01 (allopurinol risk). AS patients prescribed allopurinol for concurrent gout — common given shared metabolic risk factors — benefit from knowing their HLA-B*58:01 status. Whole genome sequencing delivers all of these results from a single DNA sample.

Ankylosing Spondylitis — HLA-B27 present in 90-95% of patients but still taking an average of 7-10 years to diagnose, during which irreversible sacroiliac and spinal joint damage accumulates without anti-inflammatory treatment.

Ankylosing Spondylitis — HLA-B27

Standard HLA-B27 commercial tests report positive/negative without subtype. Complete HLA-B typing from whole genome sequencing identifies the specific B27 subtype — differentiating high-risk from low-risk subtypes that are clinically indistinguishable by standard testing.

HLA-B*27:06 tests B27-positive but confers much lower AS risk than B*27:05 — subtype matters

The same test that evaluates HLA-B27 also covers all other pharmacogenomically actionable HLA alleles

Others in Autoimmune & Inflammatory

One test. A lifetime of answers.

HLA-B27:06 tests B27-positive but confers much lower AS risk than B27:05 — subtype matters